Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 198 entries
View as:

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03755115 Org: User:
Start: 02/01/19 End: 05/31/20 Due: 05/31/21

SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06819319 Org: User:
Start: 06/23/25 End: 12/31/30 Due: 12/31/31

Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06394661 Org: User:
Start: 04/28/24 End: 12/30/28 Due: 12/30/29

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06860529 Org: User:
Start: 04/15/25 End: 03/31/30 Due: 03/31/31

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase: N/A Priority: Normal
NCT ID: NCT06927180 Org: User:
Start: 04/16/25 End: 12/01/30 Due: 12/01/31

RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06545201 Org: User:
Start: 08/01/24 End: 04/01/27 Due: 04/01/28

A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03424291 Org: User:
Start: 07/05/17 End: 07/31/19 Due: 07/31/20

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03691051 Org: User:
Start: 11/20/18 End: 12/30/24 Due: 12/30/25

Camrelizumab Combined With Apatinib Mesylate

Phase: N/A Priority: Normal
NCT ID: NCT05380986 Org: User:
Start: 05/20/22 End: 05/01/25 Due: 05/01/26

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Phase: N/A Priority: Normal
NCT ID: NCT05189483 Org: User:
Start: 01/01/22 End: 07/30/24 Due: 07/30/25

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03457337 Org: User:
Start: 03/28/18 End: 10/31/21 Due: 10/31/22

Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05718778 Org: User:
Start: 03/20/23 End: 03/31/24 Due: 03/31/25

Anti-emetic Prophylaxis With or Without Dexamethasone

Phase: N/A Priority: Normal
NCT ID: NCT05242874 Org: User:
Start: 02/01/22 End: 08/15/23 Due: 08/15/24

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05474690 Org: User:
Start: 05/11/22 End: 08/30/24 Due: 08/30/25

Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06888531 Org: User:
Start: 03/08/25 End: 12/31/27 Due: 12/31/28

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04901754 Org: User:
Start: 07/14/21 End: 03/31/23 Due: 03/31/24

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Phase: N/A Priority: Normal
NCT ID: NCT03263208 Org: User:
Start: 08/16/17 End: 07/31/19 Due: 07/31/20

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Phase: N/A Priority: Normal
NCT ID: NCT03163381 Org: User:
Start: 04/11/17 End: 04/11/19 Due: 04/11/20

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05296577 Org: User:
Start: 03/22/22 End: 12/01/24 Due: 12/01/25

Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain

Phase: N/A Priority: Normal
NCT ID: NCT06897917 Org: User:
Start: 04/30/25 End: 12/31/25 Due: 12/31/26

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06554028 Org: User:
Start: 08/31/24 End: 12/31/27 Due: 12/31/28

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06749730 Org: User:
Start: 04/01/24 End: 06/30/27 Due: 06/30/28

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase: N/A Priority: Normal
NCT ID: NCT06231680 Org: User:
Start: 01/19/24 End: 09/30/25 Due: 09/30/26

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Phase: N/A Priority: Normal
NCT ID: NCT04055792 Org: User:
Start: 09/11/19 End: 05/01/23 Due: 05/01/24

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT05162898 Org: User:
Start: 01/31/22 End: 12/31/25 Due: 12/31/26